title: [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
abstract: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are rare but an increase in incidence has been recognized worldwide. Approximately 70 % of NETs are localized in the gastrointestinal tract and in the pancreas, other locations are in the lungs (25 %) and rarely in the skin, urogenital tract and ovaries. Depending on the size, localization, grading (G1-G3) and production of hormones, the symptoms of patients can greatly vary. Outcome and survival of patients depend on the biological behavior and grading of the NET. Patients with a well differentiated G1 grade NET have a slow, sometimes also benign course over decades even with metastases in contrast to patients with G3 grade NETs. These tumors exhibit an aggressive behavior and patient survival is short. Liver and lymph node metastases are common (about 50 %) in GEP-NETs even at the initial diagnosis. The 5-year and 10-year survival of patients with GEP-NETs is increasing (currently approximately 80 % and 60 %, respectively), especially when a multidisciplinary team (e.g. surgery, endocrinology, oncology, nuclear medicine and gastroenterology) manages GEP-NET patients.
authors.affiliation: Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Frankfurt am Main, Theodor Stern Kai 7, 60590, Frankfurt am Main, Deutschland, Katharina.Holzer@kgu.de.
authors.forename: K
authors.initials: K
authors.lastname: Holzer
mesh_terms: D003131:Combined Modality Therapy; D003299:Cooperative Behavior; D018450:Disease Progression; D006801:Humans; D033183:Interdisciplinary Communication; D007414:Intestinal Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D064847:Multimodal Imaging; D060787:Neoplasm Grading; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D049268:Positron-Emission Tomography; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
references.citation: Dtsch Arztebl Int. 2011 May;108(18):305-12
references.pmid: 21629514
references.citation: Mol Pharm. 2011 Oct 3;8(5):1775-82
references.pmid: 21800885
references.citation: J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
references.pmid: 22723327
references.citation: World J Surg. 2000 Nov;24(11):1402-8
references.pmid: 11038214
references.citation: Neuroendocrinology. 2012;95(2):88-97
references.pmid: 22261972
references.citation: Am J Clin Oncol. 2008 Jun;31(3):271-9
references.pmid: 18525307
references.citation: Zentralbl Chir. 2014 Jun;139(3):276-83
references.pmid: 23042103
references.citation: Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
references.pmid: 21349409
references.citation: Neuroendocrinology. 2012;95(2):135-56
references.pmid: 22262080
references.citation: Lancet Oncol. 2014 Jan;15(1):e8-21
references.pmid: 24384494
references.citation: Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6
references.pmid: 16327485
references.citation: Neuroendocrinology. 2012;95(2):98-119
references.pmid: 22261919
references.citation: Endocr Relat Cancer. 2010 Oct 05;17(4):909-18
references.pmid: 20702725
references.citation: World J Gastroenterol. 2014 Jan 7;20(1):118-25
references.pmid: 24415864
references.citation: Neuroendocrinology. 2012;95(2):74-87
references.pmid: 22262004
references.citation: J Nucl Med. 2007 Apr;48(4):508-18
references.pmid: 17401086
references.citation: World J Gastroenterol. 2013 Dec 21;19(47):9012-9
references.pmid: 24379626
references.citation: Endoscopy. 2010 Aug;42(8):664-71
references.pmid: 20669078
references.citation: N Engl J Med. 2011 Feb 10;364(6):501-13
references.pmid: 21306237
references.citation: Ann Surg Oncol. 2006 Apr;13(4):572-81
references.pmid: 16511671
references.citation: Neuroendocrinology. 2012;95(2):120-34
references.pmid: 22261872
references.citation: Gut. 2012 Jan;61(1):6-32
references.pmid: 22052063
references.citation: N Engl J Med. 2011 Feb 10;364(6):514-23
references.pmid: 21306238
references.citation: Neuroendocrinology. 2012;95(2):157-76
references.pmid: 22262022
references.citation: Surgery. 2011 Jul;150(1):75-82
references.pmid: 21683859
references.citation: N Engl J Med. 2009 Jan 8;360(2):195-7
references.pmid: 19129539
references.citation: Neuroendocrinology. 2011;93(4):223-9
references.pmid: 21358176